Importantly, this improvement did not come with a higher risk of major bleeding, a common concern with blood-thinning drugs. The findings were presented at the European Society of Cardiology Congress in Madrid and published simultaneously in The Lancet.

Why Aspirin Was the Default Choice

For many years, doctors have routinely prescribed low-dose aspirin to patients with coronary artery disease—the most common type of heart disease—to help lower the risk of blood clots. Aspirin makes blood less likely to clot, lowering the chances of blockages in narrowed arteries. This approach has been central to preventing repeat heart attacks and strokes.

Despite its popularity, aspirin has always carried a risk of gastrointestinal bleeding and, in some cases, has not been as effective as hoped over the long term.

Clopidogrel, which has been in use since the late 1990s, works differently by blocking a platelet receptor called P2Y₁₂. It has usually been given alongside aspirin as part of dual antiplatelet therapy or prescribed to patients who cannot tolerate aspirin. Until now, it was not considered a superior option for long-term use on its own.

What the Study Found

The new analysis combined data from seven clinical trials that followed nearly 29,000 patients with coronary artery disease. These patients came from different backgrounds and included those who had undergone stent placement or had experienced acute coronary syndromes.

Across this broad group, clopidogrel consistently performed better than aspirin. Patients taking clopidogrel experienced fewer major cardiovascular and cerebrovascular events, while rates of bleeding were essentially the same as those in the aspirin group.

Patients predicted to have a weaker response to clopidogrel because of genetic or clinical factors still showed better outcomes than those taking aspirin.

Evidence from Other Clinical Trials

The results align with findings from earlier studies. The HOST-EXAM trial, which followed more than 5,000 patients in South Korea after stent placement, reported fewer heart attacks, strokes, and bleeding complications in patients treated with clopidogrel instead of aspirin over almost six years.

Another trial, SMART-CHOICE 3, found that clopidogrel reduced the combined risk of death, heart attack, and stroke in high-risk patients compared to aspirin, again without raising bleeding risk. Together, these studies strengthen the case for clopidogrel as a safer and more effective long-term treatment option.

Implications for Patients and Guidelines

The latest findings indicate that clopidogrel may emerge as the favored option for long-term prevention of heart attacks and strokes in people with coronary artery disease. Experts believe the drug’s generic availability, affordability, and proven effectiveness make it suitable for widespread use. However, some considerations remain.

Clopidogrel is a prescription-only drug, unlike aspirin, which can be bought over the counter. Genetic variations in how patients metabolize clopidogrel may also influence its effectiveness in some cases, although the current analysis indicates benefits are still widespread.

Certain acid-reducing medications, such as omeprazole, may interfere with clopidogrel’s action, which means doctors will need to guide patients carefully on safe combinations.

Researchers emphasize that further studies on cost-effectiveness and outcomes in more diverse populations are needed before treatment guidelines are updated worldwide. Still, the data strongly indicate that clopidogrel provides superior long-term protection without added risks.

[Source]

The post Clopidogrel Outperforms Aspirin for Long-Term Heart Protection, Study Shows appeared first on Medical Journal Daily.

The findings suggest that dietary choices could help manage high blood pressure in older age, a condition linked to greater risks of heart disease, heart attack, and stroke.

Two Weeks, Twice a Day

The study involved 36 adults in their 60s and 70s and compared their responses with 39 younger adults under 30.

Participants drank concentrated beetroot juice twice a day over a two-week period. They also took a placebo version, with nitrate removed, for another two weeks.

Older adults saw a noticeable drop in blood pressure after the nitrate-rich beet juice period, but the same was not true when they consumed the placebo. Younger adults, despite drinking the same juice, did not experience a significant change in blood pressure.

The Microbiome Connection

The researchers highlighted the oral microbiome, the collection of bacteria living in the mouth, as a central factor. In older adults, beet juice led to fewer potentially harmful bacteria such as Prevotella and more beneficial bacteria such as Neisseria.

These bacteria are essential because they help convert dietary nitrate into nitric oxide. Nitric oxide helps blood vessels loosen, which makes circulation smoother and reduces blood pressure. As people age, their natural ability to produce nitric oxide declines, making them more reliant on this bacterial pathway.

While younger adults also experienced microbiome changes, their blood pressure did not fall. Researchers suggest this is because younger people already produce more nitric oxide naturally, so extra dietary nitrate has less impact. In contrast, older adults tend to have higher blood pressure and less nitric oxide, making them more responsive to dietary interventions.

Expert Views

Professor Anni Vanhatalo from the University of Exeter explained that increasing nitrate-rich vegetables in the diet could be a simple, low-cost way to support vascular health in older age. She noted that beets are not the only option—spinach, rocket (arugula), fennel, celery, and kale also provide dietary nitrate.

Co-author Professor Andy Jones added that these results pave the way for larger studies that consider lifestyle factors and differences between men and women in response to dietary nitrate.

Dr. Lee Beniston of the UK’s Biotechnology and Biological Sciences Research Council, which helped fund the work, said the study highlights how nutrition, oral bacteria, and ageing are closely linked.

Other Research on Beets and Blood Pressure

This is not the first time beets have been linked to heart health. Previous meta-analyses found that beetroot juice can reduce systolic blood pressure in adults. The effects, however, vary depending on dose, duration, and individual health conditions.

Some experts also caution that excessive nitrates can be harmful, especially if they form compounds called nitrosamines in the stomach. For most people, however, eating vegetables high in nitrates is safe and beneficial.

Practical Takeaways

For older adults looking to support heart health, small dietary changes may help:

Daily habit: A small shot of beetroot juice once or twice a day may reduce blood pressure in just two weeks.

Alternative vegetables: Spinach, celery, rocket, and kale also provide nitrates.

Oral care: Avoid strong antiseptic mouthwashes, which can wipe out helpful bacteria that aid nitrate conversion.

Heart health basics: Combine a nitrate-rich diet with exercise, reduced salt intake, and good sleep for long-term benefits.

[Source]

The post Beet Juice May Lower Blood Pressure in Older Adults in Just Two Weeks appeared first on Medical Journal Daily.

However, the study also reveals a surprising and critical distinction: not all bodies of water are created equal when it comes to human health. Living within roughly 30 miles of the ocean or gulf was tied to a longer lifespan, but city residents near inland rivers and lakes showed the reverse trend, averaging about 78 years—slightly below the national norm.

The Coastal Advantage: More Than Just a View

The study’s lead researcher, Jianyong “Jamie” Wu, and his team delved into the complex factors that might explain this stark difference. Their analysis points to a mix of environmental and social factors that give coastal areas a significant health advantage.

One of the most significant findings was the difference in climate. Compared to inland locations, coastal areas usually have gentler climates with cooler summers and far fewer days of extreme heat. These cooler summers can reduce the risk of heat-related illnesses and stress on the body. This is a crucial finding, as rising global temperatures have been linked to an increase in mortality, particularly in urban heat islands.

Air quality also tends to be better along the coast, where steady sea breezes scatter pollutants and keep the atmosphere cleaner. This contrasts sharply with many inland cities situated along rivers, which often have higher levels of air pollution from industry, vehicles, and other urban sources.

The study also highlighted the socioeconomic benefits of coastal living. Coastal areas often boast higher incomes and greater opportunities for outdoor recreation, such as walking, cycling, and water sports. These factors contribute to a healthier lifestyle, reducing the risk of conditions like obesity and heart disease.

Earlier studies have connected water proximity with better health, but this research is the first to closely compare how different kinds of “blue spaces” influence life expectancy.

Inland Urban Waters: A Different Story

So why do urban residents living near inland rivers and lakes face a shorter life expectancy? The researchers suggest that pollution, poverty, and a lack of safe recreational opportunities play a key role.

Many of America’s major rivers and lakes have historically been and continue to be industrial and transportation hubs. This has led to higher levels of air and water pollution, which can negatively impact public health.

The study also noted that these urban areas often face higher rates of poverty, which is a well-known determinant of health. Lower-income neighborhoods may have less access to quality healthcare, healthy food options, and safe public spaces for physical activity.

Furthermore, the risk of natural disasters like flooding is a significant factor. Flooding can disrupt communities, damage infrastructure, and expose residents to contaminated water, all of which can have long-term health consequences. Tidal movements follow a predictable rhythm, but floods along rivers can strike suddenly and cause severe damage in nearby communities.

A Call to Re-evaluate Our “Blue Spaces”

The findings of this groundbreaking study challenge the widely held assumption that any proximity to water is beneficial. It forces a re-evaluation of how we view and manage our “blue spaces.” The study’s authors emphasize that health inequities, driven by complex environmental and social factors, are a major reason for the differences they observed.

In recent years, life expectancy in the United States has dropped more sharply—and recovered more slowly—than in other high-income countries. This study provides valuable insight into this trend, suggesting that environmental factors tied to geography and socioeconomic status are playing a key role.

While moving to the coast isn’t a realistic option for everyone, the study offers a powerful message for public health officials and urban planners. It highlights the need to address pollution, improve access to safe recreational spaces, and mitigate environmental risks in all communities, especially those near inland waters.

The key to a longer, healthier life may not be just living by the water, but living in a community where the water—and all the factors that come with it—are clean, safe, and supportive of a healthy lifestyle.

The post Living Near the Ocean May Add Years to Your Life, New Study Finds appeared first on Medical Journal Daily.

The study, published in Nature Aging, found that FTL1 builds up in the hippocampus, the brain’s memory center, as mice get older. Too much of this protein disrupts brain function. Older mice with elevated FTL1 performed poorly on memory tasks. To confirm the link, scientists boosted FTL1 in younger mice.

To confirm the link, scientists boosted FTL1 in younger mice. These healthy mice quickly developed memory problems similar to older ones. But when scientists lowered FTL1 levels in aging mice, something remarkable happened: their memory improved to the level of much younger mice.

How FTL1 Affects the Brain

FTL1 helps store iron inside cells, but when it builds up in the brain, it disrupts how neurons generate and use energy. Neurons need energy to build and maintain connections, which are the pathways for learning and memory.

When FTL1 levels rise, neurons lose power. They cannot store information as effectively, leading to forgetfulness. Scientists also observed that older mice with high FTL1 had fewer connections between brain cells.

The team used advanced tools, including viruses and genetic methods, to change FTL1 levels. They then put mice through memory and learning challenges, such as solving mazes and recognizing objects. After reducing FTL1, older mice performed almost as well as young mice, proving that brain function could be restored.

The research also tested metabolism. Researchers discovered that when FTL1 levels rise, neurons struggle to produce enough energy. When they added NADH, a compound that helps with cell energy, memory problems improved. This suggests that targeting brain energy systems could be another way to help with memory loss reversal.

What This Means for Humans

While the results are exciting, the research is still at an early stage. The experiments were done only in male mice, and the human brain is far more complex. A treatment that works in mice may not work the same way in people.

Currently, there are no safe drugs that directly reduce FTL1 in humans. The methods used in the study involved genetic tools, not medicines. Researchers warn that it could take years before this discovery leads to new therapies.

Still, the findings are important because they focus on normal, age-related memory decline, not just diseases like Alzheimer’s. Almost everyone experiences some memory loss with age. By targeting FTL1, scientists may one day find a way to help a much larger group of people.

In the United States, between six and 12 million people over 65 live with mild cognitive impairment, a condition that often leads to dementia. About one-third of them develop Alzheimer’s within five years. For these individuals, new options for memory loss reversal could make a huge difference.

A New Direction in Brain Research

For decades, dementia research has centered on proteins like beta-amyloid and tau, which form clumps and tangles in the brain. The UCSF study adds a new angle by showing that iron-related proteins and energy systems may also be key to memory decline.

By focusing on FTL1, scientists are opening doors to treatments that could help almost everyone as they grow older—not just those with Alzheimer’s disease.

[Source]

The post Scientists Find Way to Reverse Memory Loss in Mice appeared first on Medical Journal Daily.

The new testing system is currently undergoing trials in Cumbria and the North East of England, and health officials plan to extend its availability to the rest of the UK before the end of the year. If successful, it could offer lessons for healthcare systems worldwide, including the United States, where over 37 million adults live with diabetes and millions remain undiagnosed.

How the Test Works

PocDoc’s test is built around the HbA1c marker, widely recognized as the benchmark for identifying and tracking type 2 diabetes. HbA1c measures average blood glucose levels over the past two to three months, offering a reliable picture of long-term sugar control rather than just a single reading. To use the test, patients begin with a simple finger-prick to provide a small blood sample.

The sample is then applied to PocDoc’s patented microfluidic test cartridge, which is designed to capture and process the biomarker. Using the companion smartphone app, the cartridge is scanned, and results are generated in less than 10 minutes, eliminating the need for laboratory analysis.

By shifting screening away from clinics and into homes, pharmacies, and community spaces, the technology reflects a broader trend in digital health—giving individuals greater control and convenience in monitoring chronic conditions such as diabetes.

Why It Matters for Public Health

Type 2 diabetes is one of the most preventable chronic conditions, yet it continues to grow rapidly worldwide. In the UK, around 5.2 million people live with the disease, and another 1.3 million are undiagnosed. Treating diabetes and its complications costs the National Health Service (NHS) about £8.8 billion annually, nearly 10% of its total budget.

In the United States, the challenge is even greater. The Centers for Disease Control and Prevention (CDC) reports that diabetes costs the U.S. healthcare system $327 billion each year, with nearly $1 in every $4 healthcare dollars spent on treating the disease. Alarmingly, 96 million Americans are estimated to have prediabetes, but the majority do not know it.

For both the NHS and U.S. healthcare providers, earlier detection could significantly reduce long-term costs and complications. Lifestyle interventions, such as improved diet, exercise, and weight management, have been shown to reduce the risk of type 2 diabetes by nearly 50% if introduced early.

Professor Julia Newton from Health Innovation Northeast and North Cumbria highlighted this potential: “Type 2 diabetes can often be prevented or even reversed through early detection and lifestyle change. Making tests available at the touch of a button could be a game-changer.”

Implications for U.S. Healthcare

The United States faces unique challenges in managing diabetes. While annual screenings are recommended for high-risk groups, access remains uneven—particularly in rural areas, among uninsured populations, and in communities with limited primary care.

Smartphone-based testing could help bridge these gaps. With more than 85% of U.S. adults owning a smartphone, app-driven diagnostics could reach populations underserved by traditional healthcare. Pharmacies, employer wellness programs, and telehealth providers could integrate rapid HbA1c testing into their services, helping millions access earlier screenings.

That said, scaling such a system in the U.S. would require FDA approval, insurance integration, and careful oversight to ensure accuracy. The FDA has previously flagged risks with some health apps that failed to provide reliable alerts. Ensuring data security and equitable access will also be critical.

Still, experts believe that digital-first models could save billions annually by reducing hospitalizations, dialysis treatments, and cardiovascular emergencies linked to late-diagnosed diabetes.

The Future of At-Home Testing

The diabetes test is not PocDoc’s first foray into digital diagnostics. The company also launched a Healthy Heart Check, an at-home cholesterol and cardiovascular risk screening kit. Its success indicates a broader shift toward self-administered, technology-driven preventive care.

If the diabetes test proves successful in the UK, expansion into other markets could follow. For U.S. patients, this would mean faster access to critical health information and greater control over managing their risk factors.

As healthcare systems worldwide grapple with rising chronic disease costs, tools like the PocDoc test show how technology and preventive medicine can work hand-in-hand. Instead of waiting for symptoms to appear or results to trickle in from distant labs, patients could soon hold answers in the palm of their hand—literally.

[Source]

The post Diabetes Smartphone Test Could Diagnose Condition in Under 10 Minutes appeared first on Medical Journal Daily.

This research not only offers a new therapeutic avenue but also sheds light on the shared biological mechanisms that may link autism and epilepsy.

The Study

The study focused on the reticular thalamic nucleus (RT), a part of the brain responsible for processing sensory information. The researchers used mouse models of autism spectrum disorder (ASD), which were genetically modified with mutations in the CNTNAP2 gene, a gene strongly associated with autism.

These mice exhibited classic autism-like behaviors, including repetitive grooming, social withdrawal, hyperactivity, and an increased susceptibility to seizures. The scientists discovered that the neurons in their RT were overactive, a phenomenon linked to strong currents in what are known as T-type calcium channels.

The team then introduced Z944, also known as ulixacaltamide, a drug being studied as a potential treatment for seizure disorders. Z944 is a T-type calcium channel antagonist, meaning it works by blocking these specific currents.

The results were nothing short of remarkable. After administering just one dose of Z944, the mice showed a significant reversal of their autistic behaviors. Their repetitive grooming decreased, they became more socially interactive, and their hyperactivity was reduced.

The drug appeared to “quiet” the overactive RT region, leading to a profound change in their behavior. This finding was further validated when the researchers genetically modified the mice to have increased activity in the RT, causing the autistic behaviors to return.

This suggests that Z944’s ability to suppress this specific brain region is the key to its therapeutic effect.

The Overlap Between Autism and Epilepsy

The findings of this study provide crucial evidence for a long-suspected connection between autism and epilepsy. Autistic individuals are up to 30 times more likely to develop epilepsy than the general population. This high comorbidity has led experts to believe that the two conditions may share underlying biological mechanisms, and this new research strongly supports that theory.

The study suggests that the same overactive neural circuits and channels in the RT that contribute to autistic symptoms may also be a factor in seizure activity. This potential overlap not only explains why the conditions often coexist but also highlights a promising new target for treatment that could address both simultaneously.

While the prospect of a single-dose treatment is exciting, the researchers are quick to emphasize that these findings are still preliminary and based on animal models.

It remains unclear how these results will translate to humans. However, the study provides a critical framework for future research. The scientists note that the next steps should focus on understanding how the RT’s influence on the broader brain circuitry affects the full spectrum of ASD behaviors.

This knowledge could pave the way for highly precise, circuit-specific interventions tailored to the needs of individuals with autism. As Z944 continues its clinical trials for epilepsy, its potential as a dual-purpose drug for both epilepsy and autism remains a captivating possibility that could fundamentally change the lives of millions.

[Source]

The post New Seizure Drug Shows Promise in Reversing Autism Symptoms in Mice appeared first on Medical Journal Daily.

The illness is defined by an overwhelming and unrelenting fatigue that does not improve with rest, often coupled with pain, cognitive difficulties, and post-exertional malaise—a sudden worsening of symptoms after even small amounts of physical or mental activity. Despite its impact, there has been no diagnostic test, no clear biological explanation, and no proven cure.

Now, a major genetic study is beginning to change that narrative. The DecodeME project, launched in 2022 and led by scientists at the University of Edinburgh with support from patient advocacy groups, has provided the strongest evidence yet that biology—rather than behavior or psychology—plays a central role in ME/CFS.

Eight Genetic Signals—What They Reveal

Researchers examined DNA samples from more than 15,000 people with the illness and compared them to over 250,000 individuals without it. What they found was striking: eight regions of DNA where genetic differences were far more common among patients than in the general population.

These differences, often referred to as “genetic signals,” appear to cluster around two key biological systems—the immune system and the nervous system. Some of the genes identified are known to influence how the body responds to infection, a finding that echoes the experiences of many patients who report that their illness began after a viral or bacterial illness.

Others are linked to pathways involved in pain regulation, which may help explain why chronic pain is such a common feature of the condition.

Importantly, the study also showed that these genetic differences are not associated with psychiatric conditions such as depression or anxiety, helping to counter the long-standing misconception that ME/CFS is primarily psychological in nature.

Implications

The implications of these findings are significant, though researchers caution that they are only the beginning. The genetic associations discovered by DecodeME cannot yet be used to diagnose the illness, nor do they immediately translate into treatment.

What they do provide, however, is a roadmap for future research—clues that point scientists toward the biological processes most likely driving ME/CFS. By focusing on immune and neurological pathways, researchers may be able to develop targeted studies and, eventually, new therapies that address the underlying mechanisms rather than just the symptoms.

For patients, the study represents more than just scientific progress—it is also a moment of validation. ME/CFS has historically been misunderstood, with many sufferers facing disbelief from clinicians, employers, and even friends or family. The discovery that the illness is written, at least in part, into the genome underscores that it is not imagined, but rooted in biology. As Professor Chris Ponting, who leads the DecodeME study, has noted, these results mark a turning point in how the illness is perceived within the medical and research communities.

Future Directions

The DecodeME team is continuing its work, expanding the study to include participants from more diverse backgrounds and conducting deeper analyses of genetic variation. They have also made their dataset available to scientists around the world in the hope that collaboration will accelerate discoveries.

While it may take years to translate these findings into practical treatments, the momentum is now firmly on the side of progress. For a patient community that has long waited for recognition and solutions, this study offers both a clearer biological foundation and a renewed sense of hope.

[Source]

The post Major Study Reveals Genetic Roots of Chronic Fatigue Syndrome appeared first on Medical Journal Daily.

The peer-reviewed paper, published in PAIN, used both careful pain testing and brain imaging to unpack why this works.

What the new study found

Researchers induced sensitization in the nervous system of 30 healthy adults using a standard high-frequency stimulation model, which reliably mimics features of long-term, neuropathic-like pain. Participants then experienced one of three conditions: a 45-minute 360° VR nature session (waterfalls in Oregon), the same footage on a regular 2D screen, or no intervention.

Only the immersive VR condition meaningfully reduced the development and spread of mechanical secondary hyperalgesia (a hallmark of sensitized pain processing), and the benefit persisted through the end of the session. Crucially, relief scaled with “presence”—the stronger the feeling of being in nature, the greater the analgesia.

University summaries note that immersive VR nature was roughly twice as effective as 2D video at reducing pain experience, and that reductions in pain-related sensitivity were still evident at least five minutes after the session. For people who can’t easily access green spaces—like many living with chronic conditions—this matters: VR can deliver a therapeutically rich “dose” of nature on demand.

How it may work in the brain

The researchers also tested brain activity with MRI scans while participants experienced pain from a cold gel. They found that watching nature in VR changed how certain brain regions ‘talked’ to each other. Specifically, it seemed to help the brain’s natural pain-control system kick in, so fewer pain signals spread through the nervous system.

The effect was strongest when people really felt like they were inside the virtual nature scene, which suggests that the sense of presence helps the brain turn down pain more effectively.

The Exeter work builds on a broader line of evidence that nature exposure—virtual or real—tempers pain. Earlier in 2025, a Nature Communications study showed that simply watching well-designed nature videos lowered both reported pain and brain activity tied to pain processing compared with urban or indoor scenes. The authors argued this wasn’t placebo; the brain’s nociceptive (pain-signal) pathways were genuinely less reactive.

VR isn’t a magic bullet, but it is becoming a legitimate tool in multimodal pain management. In 2021, the U.S. FDA authorized the first at-home VR therapeutic for chronic low-back pain—a program grounded in behavioral skills rather than nature content—after randomized trials showed meaningful, durable benefits.

The regulatory milestone signaled that immersive, non-drug approaches can cross the bar for safety and effectiveness. Nature-based VR adds another, potentially complementary, path: it leans on our hard-wired response to natural environments to turn down pain signaling—with minimal side effects.

What this means for people with chronic pain

For clinics, hospitals, and care homes—places where stepping outside isn’t always feasible—curated VR nature sessions could offer accessible, low-risk relief and pair easily with physical therapy, CBT, or medications.

The practical takeaways from the new study are straightforward: aim for immersive, high-quality 360° nature content; run sessions long enough to let presence build (the study used ~45 minutes); and measure outcomes beyond immediate distraction, since benefits persisted.

The PAIN trial simulated chronic-like sensitization in healthy volunteers; it didn’t test people diagnosed with chronic pain, and the sample was small.

We still need large, real-world trials in specific conditions (e.g., neuropathic pain, fibromyalgia), dose-finding work (how often, how long), and comparisons across different natural environments and personalization levels. But taken together with the 2025 neuroimaging results and past VR analgesia research, the case for “virtual nature as therapy” is getting stronger.

[Source]

The post Virtual Reality Nature Scenes Found to Ease Chronic Pain, Study Shows appeared first on Medical Journal Daily.

How Light at Night Disrupts the Body

Nelson’s research shows that artificial light at night interferes with the body’s internal clock, suppressing melatonin production and disrupting the natural light–dark cycle that governs many biological functions. This disruption affects multiple systems:

Brain and mood: Exposure to dim light during normal sleep hours has been shown in animal studies to increase brain inflammation, reduce levels of brain-derived neurotrophic factor (BDNF), and cause behaviors linked to depression.

Metabolism: Nighttime light alters circadian gene expression, which can impair insulin sensitivity, promote weight gain, and disturb glucose regulation.

Immune function: Irregular light exposure can suppress normal immune responses or cause chronic low-grade inflammation, increasing vulnerability to illness.

These effects can appear even with relatively low light levels—around 5 lux, similar to the glow from a dim bedside lamp. Research has linked such exposure to a greater risk of metabolic disorders, cardiovascular disease, and mood disorders.

From Laboratory Studies to Clinical Trials

While much of the foundational work comes from controlled lab experiments, Nelson’s team is translating these findings into real-world applications through clinical trials. In hospital intensive care units (ICUs), patients are often exposed to bright artificial light around the clock, which may slow recovery. Nelson’s group is testing interventions such as adjusting light wavelengths and timing to improve outcomes for stroke and cardiac surgery patients.

Another study focuses on night-shift nurses, who are at high risk for sleep problems and mood disturbances. By using blue-light visors at specific times, the research aims to help reset their circadian rhythms, potentially improving cognitive performance and overall well-being. These trials explore whether similar strategies could support shift workers in other industries, where irregular schedules make it hard to maintain natural sleep–wake cycles.

Nelson also points out that the time of day can affect research results. Experiments done in the morning might give different outcomes than those done in the evening, but many studies don’t record or control for this. Keeping track of when tests are done could make biomedical research more consistent and reliable.

Practical Steps for Protecting Circadian Health

Nelson’s work underscores that small lifestyle changes can help protect circadian rhythms and reduce the health risks of artificial light at night. Strategies supported by current evidence include:

Limit blue light exposure after sunset: Use warmer-toned light bulbs in the evening and enable night mode on screens.

Block ambient nighttime light: Blackout curtains or eye masks can reduce intrusion from streetlights and outdoor lighting.

Maintain regular sleep–wake cycles: Going to bed and waking up at consistent times helps reinforce natural rhythms.

Increase daylight exposure: Spending at least 30 minutes outside in the morning boosts alertness and helps anchor the circadian clock.

Nelson’s recent book, Dark Matters, offers a detailed guide for the public on aligning daily habits with biological timing to improve long-term health.

Artificial light at night is now recognized as a growing public health concern, with research linking it to chronic disease risk and mental health challenges. Nelson’s investigations—from molecular changes in the brain to patient care in the ICU—show that circadian disruption is not just a sleep issue but a multi-system health problem. Adopting circadian-friendly lighting practices and reducing nighttime light exposure could play a key role in preventing illness and improving well-being.

[Source]

The post How Light at Night Affects Brain, Mood, and Metabolism appeared first on Medical Journal Daily.

How the Gel Works

Many people with diabetes develop chronic wounds, especially on the feet, that can take months to heal—or never fully recover. One big reason is poor blood flow. In these wounds, a protein called TSP-1 acts like a “stop signal” for new blood vessels, preventing the tissue from getting the oxygen and nutrients it needs.

The new hydrogel is designed to silence that “stop signal.” It contains tiny bubble-like structures called extracellular vesicles, which naturally carry signals between cells. In this case, the vesicles have been engineered to carry a genetic message called miR-221-3p. This message tells the body to lower TSP-1 levels, allowing new blood vessels to form.

These vesicles are mixed into a gelatin-based material called GelMA hydrogel. The hydrogel acts like a soft scaffold, holding the vesicles in place at the wound site and slowly releasing them over time. This ensures that the treatment is delivered steadily, rather than all at once, which helps maintain a healing-friendly environment.

When tested on diabetic mice, the wounds treated with the gel closed significantly faster than untreated wounds. Within just 12 days, about 90 percent of the wound area had healed in the treated group, compared to much slower progress in the control group. The treated wounds also showed a greater number of tiny new blood vessels, confirming that angiogenesis had been restored.

The study’s lead author, Dr. Chuan’an Shen, noted that combining advanced tissue engineering with molecular biology allowed them to address the root cause of poor healing in diabetic wounds.

Why the Hydrogel Matters

The vesicles are mixed into a GelMA hydrogel, which feels a bit like soft jelly. This material clings to the wound, slowly releasing the healing particles over time. It also mimics the body’s own tissue structure, giving cells a good environment to grow.

In lab tests, this combination not only closed wounds faster but also increased the number of tiny new blood vessels in the healing tissue.

Diabetic wounds are a major health problem worldwide. They are difficult to treat with existing methods, and slow healing can cause serious complications.

If this hydrogel treatment works as well in humans as it did in mice, it could transform treatment for diabetic foot ulcers, which affect millions of people worldwide. Faster healing means fewer infections, a lower risk of amputations, and better quality of life.

The approach might also be adapted to help other stubborn wounds, such as those caused by poor circulation, or even to help repair other types of tissue like bone or cartilage.

Right now, the gel has only been tested in mice. The next step is to carry out clinical trials to see if it works safely and effectively in people. If successful, the diabetic wound-healing hydrogel could become a valuable tool for doctors, reducing recovery times from months to days.

[Source]

The post Smart Gel Speeds Up Healing for Diabetic Wounds appeared first on Medical Journal Daily.